Association of the rate of bilirubin decrease with major morbidity in patients undergoing preoperative biliary drainage before pancreaticoduodenectomy

Narongsak Rungsakulkij, Varinthip Thongchai, Wikran Suragul, Watoo Vassanasiri, Pongsatorn Tangtawee, Paramin Muangkaew, Somkit Mingphruedhi and Suraida Aeesoa

Abstract

Objective: The objective of this study was to examine the relationship between the rate of bilirubin decrease following preoperative biliary drainage before pancreaticoduodenectomy and postoperative morbidity.

Methods: Records of patients who underwent pancreaticoduodenectomy at the Department of Surgery in Ramathibodi Hospital between January 2008 and December 2019 were retrospectively reviewed. The patients were classified into either an adequate or inadequate drainage rate groups according to the bilirubin decrease rate. Major morbidity was defined as higher than grade II in the Clavien-Dindo classification. Risk factors for major morbidity were analyzed by logistic regression analysis.

Results: In total, 166 patients were included in the study. Major morbidity was observed in 36 patients (21.6%). Adequate biliary drainage rate was observed in 39 patients (23.4%). Patients who had major morbidity were less likely to have come from the adequate biliary drainage rate group than the inadequate group (38.9% vs. 61.1%). However, through multivariate logistic analysis, only body mass index, operative time, and pancreatic duct diameter were independent factors associated with major morbidity, whereas the bilirubin decrease rate was not.

Conclusions: Bilirubin decrease rate following preoperative biliary drainage has no significant association with major postoperative morbidity after pancreaticoduodenectomy.

Keywords
Pancreaticoduodenectomy, drainage, bilirubin, operative time, postoperative complications, morbidity

Date received: 18 March 2021; accepted: 27 July 2021

Introduction

Obstructive jaundice is a common presentation of patients with a periampullary tumor.1 The standard treatment for periampullary tumor is pancreaticoduodenectomy (PD), which is a complex surgery with high morbidity.2 Recently, there have been a number of studies reporting the poor outcomes of patients with severe jaundice who had underwent PD.3,4 The pathophysiology of a poor surgical outcome in obstructive jaundice includes the following: blockage of bile salts in the intestinal tract induces the proliferation of the normal microbial flora, dysfunction of the intestinal mucosal barrier, bacterial translocation, increasing endotoxin concentrations in the portal circulation, altered Kupffer cell function affecting the liver’s reticuloendothelial system, decreased cellular immunity, and prolonged wound healing.5 Thus, preoperative biliary drainage (PBD) prior to PD is indicated in patients with severe jaundice.6,7 However, there are contradicting studies which do not recommend routine PBD in patients undergoing PD due to the increased rate of infectious complications6,7 and the poorer oncologic outcomes when compared with patients who received upfront surgery.8

There has been a small number of studies that investigated the factors associated with the outcomes following...
PBD before PD, such as, the drainage method\textsuperscript{9,12} and the drainage duration.\textsuperscript{13} When considering the drainage method, contradicting results can be found between the endoscopic approach and the percutaneous approach. A recent systematic review reported that a percutaneous approach is preferred to an endoscopic approach due to fewer procedure-related complications and postoperative complications.\textsuperscript{9} However, there is also an argument for the endoscopic approach since the percutaneous approach can cause catheter-related complications and increased incidence of seeding metastasis.\textsuperscript{10,11} Some even suggest that endoscopic drainage should be the first-line treatment for malignant biliary tract obstructions.\textsuperscript{12} Despite the different approaches, ultimately, biliary decompression is important in severely jaundiced patients. PBD provides both a prognostic and therapeutic benefit since it can provide tissue for pathological investigations and helps restore hepatocyte function.\textsuperscript{3,14} The usual timing required for the restoration of hepatocyte functions after PBD is approximately 2 weeks.\textsuperscript{14} However, the restoration time may be delayed in some patients. The restoration of hepatocyte function can be delayed by prolonged biliary obstruction prior to drainage, infection, and any background of liver disease.\textsuperscript{14,15} Regarding any association between the restoration of the patient’s liver and hemodynamic function from the prolonged biliary obstruction with the outcome following PD, there are only a few studies investigating the association between the rate of bilirubin decrease and the outcome of PD.\textsuperscript{16,17} Thus, the aim of this study is to investigate the rate of bilirubin decrease after PBD in periampullary tumor patients, and whether the rate of the bilirubin decrease affects the outcome following PD.

Patients and methods

A total of 307 patients underwent PD at the Department of Surgery, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand from January 2008 to December 2019 and their data were retrospectively reviewed. Patients who underwent PBD were included in the study.

Ramathibodi Hospital has a routine practice for patients who are due to undergo PD. All patients undergoing PD are examined by preoperative cross-sectional dynamic imaging using either triple-phase computed tomography or magnetic resonance imaging. The indications for PBD prior to PD are severe jaundice (serum total bilirubin ≥ 5 mg/dL), malnutrition, or an operation waiting time longer than 2 weeks. In terms of the PBD method, endoscopic retrograde cholangiopancreatography (ERCP) is the first-line approach. ERCP is performed by an experienced endoscopist. Stent type selection is dependent on the surgeon’s preference. If a stent cannot be placed via an endoscopic approach, a percutaneous transhepatic biliary drainage (PTBD) is performed. PTBD is performed by an interventionist under standard procedures.

Patient data were retrospectively reviewed, including age, gender, body mass index (BMI), comorbidity, American Society of Anesthesiologists (ASA) classification, smoking history, cholangitis history, serum albumin level, serum total bilirubin level, pre-operative diagnosis, and waiting time. Waiting time is defined as the duration between PBD and surgery. Perioperative data including operative time, blood loss, pancreatic texture, and pancreatic diameter were collected.

Regarding the serum total bilirubin level, patients’ blood was taken to determine the bilirubin level prior to PBD and at multiple intervals until the patient undergo PD. The solution of non-parametric of the rate of the bilirubin using the Random-effects generalized least squares (GLS) regression model adjusted by time, presence of cholangitis, age, and serum albumin level was done to determine bilirubin level for the days the blood was not collected. The equation used is as follows

\[
Y_{\text{Total Bilirubin}} = 5.488e^{-0.003 \text{time} - 0.526 \text{cholangitis} \times \text{time} - 0.001 \text{age} \times \text{time} - 0.313 \text{alb min} \times \text{time}}
\]

The study protocol was approved by the Institutional Ethical Committee at the Faculty of Medicine, Ramathibodi Hospital (protocol number, MURA 2018/844).

Operative procedure

PD was performed by experienced hepatopancreathomobilary surgeons. Routine prophylactic antibiotic was administered 30 min before the skin incision was made. The decision to perform classical PD or pylorus-preserving PD was dependent on the surgeon’s preference. Reconstruction after resection was performed using Child’s technique, starting with the pancreaticojejunostomy, then hepaticojejunostomy and gastrojejunostomy consecutively. A trans-anastomotic pancreatic duct stent, either internal or external, was placed into selected patients depending on the surgeon’s preference. Pancreatic texture was classified as hard, firm, or soft consistency, based on palpation by the surgeon. Intra-operative blood loss was documented. Patients were transferred to a critical care unit or intermediate ward after the operation. Routine biochemical analyses of patients’ blood were performed. An oral diet was started as soon as the gastric content output was less than 400 mL/day, along with the presence of a bowel movement.

Perioperative morbidity

Postoperative morbidity were classified according to the Clavien-Dindo classification.\textsuperscript{18} Only procedure-related complications were considered. Major morbidity were defined as higher than grade II in the Clavien-Dindo classification. Postoperative pancreatic fistula (POPF) was diagnosed according to the International Study Group of Pancreatic Fistula (ISGPF) guidelines.\textsuperscript{19} POPF was classified into three categories: biochemical leakage (transient pancreatic fistula with no clinical impact), grade B (a fistula requiring a change
in management or adjustment of the clinical course) and grade C (a fistula requiring a major change in clinical management or deviation from the normal clinical course). Postoperative mortality included mortality within 90 days of the operation and in-hospital mortality.

**Statistical analysis**

The analysis of the patient characteristics was done using student’s t test for continuous variables and $\chi^2$ test or Fisher’s exact test for categorical variables. A p value of $<0.05$ was considered statistically significant. The potential risk factors were analyzed by univariate and multivariate methods using a logistics regression model. Independent risk factors were expressed as odd ratios (ORs) with 95% confidence intervals (CIs).

**Results**

**Post-drainage bilirubin decrease rate**

The rates of bilirubin decrease at post-drainage week 1, 2, 3, and 4 (compared with pre-drainage bilirubin level) were 12.0%, 23.1%, 27.9%, and 32.5%, respectively, as shown in Figure 1. According to the European Society of Gastrointestinal Endoscopy’s clinical guidelines, a decrease in total bilirubin of $<20\%$ from baseline on the seventh day post stent insertion should be considered inadequate drainage. Thus, a cutoff of 20% was used to distinguish between the adequate and inadequate drainage group in this study.

**Patient characteristics and perioperative data comparing between adequate and inadequate rate groups**

A total of 307 patients underwent PD from January 2008 to December 2019, of whom 166 underwent PBD. The epidemiology of the adequate drainage and inadequate drainage groups is displayed in Table 1. The percentage of patients who exhibited an adequate rate of bilirubin decrease was 23.4% (39/166). The inadequate group’s bilirubin decreased at a significantly lower rate (0.8 vs. 1.9, $p < 0.001$). The waiting time for PD between the two groups was not statistically different (39 days for the adequate group vs 47 days for the inadequate group, $p = 0.129$).

**Comparison between major and non-major morbidity**

Of the 166 patients included in the study, 36 patients had major postoperative morbidity (21.68%) and the remaining 130 patients had minor morbidity or no morbidity. The
clinopathological characteristics of the patients stratified by morbidity is shown in Table 2. Those with major morbidity had greater body mass index (BMI; 24.2 vs. 22.4 kg/m², p = 0.009), and longer operative time (8.8 vs. 7.9 h, p = 0.018) compared with those with minor/no morbidity. Pancreatic duct diameter was significantly smaller in patients who had major morbidity (3 vs. 4 mm, p = 0.011). Patients who had major morbidity were less likely to have come from the adequate biliary drainage rate group than the inadequate group (38.9% vs. 61.1%, p = 0.014).

**Analysis of the risk factors associated with major morbidity**

The results of the univariate and multivariate analyses of potential risk factors for major postoperative morbidity are shown in Table 3. The univariate analysis identified the following variables as being significantly associated with major morbidity: BMI (OR = 1.1; 95% CI = 1.0–1.2; p = 0.012), operative time (OR = 1.2; 95% CI = 1.0–1.4; p = 0.021), and pancreatic duct diameter (OR = 0.7; 95% CI = 0.6–0.9; p = 0.021). Multivariate analysis revealed that BMI (OR = 1.1; 95% CI = 1.0–1.2; p = 0.040), operative time (OR = 1.2; 95% CI = 1.0–1.5; p = 0.027), and pancreatic duct diameter (OR = 0.7; 95% CI = 0.6–0.9; p = 0.033) were significantly associated with major morbidity. From the univariate and multivariate analysis, bilirubin decrease rate did not associate with major morbidity.

**Discussion**

PD is a complex abdominal surgery associated with high morbidity. Preoperative optimization of patients undergoing
Table 2. Patients' perioperative characteristics comparing major and non-major morbidity.

| Data                                      | Total (n = 166) | Non-major morbidity (n = 130) | Major morbidity (n = 36) | p value |
|-------------------------------------------|-----------------|------------------------------|--------------------------|---------|
| Age (years), mean ± SD                    | 60.72 ± 11.28   | 60.56 ± 11.66                | 61.27 ± 9.93             | 0.739   |
| Gender, n (%)                              |                 |                              |                          |         |
| Male                                       | 92 (55.42)      | 74 (56.92)                   | 18 (50.00)               | 0.460   |
| Female                                     | 74 (44.58)      | 56 (43.08)                   | 18 (50.00)               |         |
| BMI (kg/m²), mean ± SD                    | 22.84 ± 3.70    | 22.45 ± 3.69                 | 24.25 ± 3.45             | 0.009   |
| DM, n (%)                                  |                 |                              |                          |         |
| No                                         | 134 (80.72)     | 102 (78.46)                  | 32 (88.89)               | 0.160   |
| Yes                                        | 32 (19.28)      | 28 (21.54)                   | 4 (11.11)                |         |
| ASA class, n (%)                           |                 |                              |                          |         |
| I                                          | 19 (11.45)      | 15 (11.54)                   | 4 (11.11)                | 0.111   |
| II                                         | 58 (34.94)      | 47 (36.15)                   | 11 (30.56)               |         |
| III                                        | 83 (50.00)      | 65 (50.00)                   | 18 (50.00)               |         |
| IV                                         | 4 (2.41)        | 3 (2.31)                     | 1 (2.78)                 |         |
| V                                          | 2 (1.20)        | 0                            | 2 (5.56)                 |         |
| Preoperative cholangitis, n (%)            | 21 (12.65)      | 16 (12.31)                   | 5 (13.89)                | 0.801   |
| Smoking, n (%)                             |                 |                              |                          |         |
| No                                         | 118 (71.08)     | 90 (69.23)                   | 28 (77.78)               | 0.317   |
| Yes                                        | 48 (28.92)      | 40 (30.77)                   | 8 (22.22)                |         |
| WBC (cell/mm³), median (IQR) n = 164       | 7375 (6100, 8750)| 7400 (6270, 8750)            | 7230 (5520, 8690)        | 0.331   |
| Hb (g/dL), median (IQR) n = 164            | 120 (11.0, 13.0)| 12.0 (11.0, 12.9)            | 12.0 (11.3, 13.1)        | 0.475   |
| Biliary intervention, n (%)                |                 |                              |                          |         |
| PTBD                                       | 6 (3.61)        | 4 (3.08)                     | 2 (5.56)                 | 0.611   |
| ERCP                                       | 160 (96.39)     | 126 (96.92)                  | 34 (94.44)               |         |
| Type of stent, n (%)                       |                 |                              |                          |         |
| Plastic                                    | 155 (98.3)      | 123 (98.4)                   | 32 (100)                 | 0.999   |
| Metallic                                   | 2 (1.27)        | 2 (1.60)                     | 0                        |         |
| Albumin (g/L), mean ± SD                  | 34.13 ± 4.94    | 34.50 ± 5.01                 | 32.78 ± 4.53             | 0.065   |
| ≥35                                        | 90 (54.22)      | 66 (50.77)                   | 24 (66.67)               | 0.090   |
| <35                                        | 76 (45.78)      | 64 (49.23)                   | 12 (33.33)               |         |
| Preoperative diagnosis, n (%)              |                 |                              |                          |         |
| Benign                                     | 23 (13.86)      | 17 (13.08)                   | 6 (16.67)                | 0.581   |
| Malignant                                  | 143 (86.14)     | 113 (86.92)                  | 30 (83.33)               |         |
| Diagnosis, n (%)                           |                 |                              |                          |         |
| Ampulla cancer                             | 63 (37.95)      | 48 (36.92)                   | 15 (41.67)               | 0.231   |
| Pancreatic cancer                          | 39 (23.49)      | 35 (26.92)                   | 4 (11.11)                |         |
| Duodenal cancer                            | 9 (5.42)        | 8 (6.15)                     | 1 (2.78)                 |         |
| Cholangiocarcinoma                         | 16 (9.64)       | 11 (8.46)                    | 5 (13.89)                |         |
| Other                                      | 39 (23.49)      | 28 (21.54)                   | 11 (30.56)               |         |
| Operative time (hr), mean ± SD             | 8.13 ± 2.16     | 7.92 ± 2.15                  | 8.87 ± 2.10              | 0.018   |
| Blood loss (ml), median (IQR)              | 800 (500, 1400) | 700 (500, 1500)              | 800 (500, 1250)          | 0.336   |
| Pancreatic texture, n (%) n = 160          |                 |                              |                          |         |
| Hard/Firm                                  | 73 (45.63)      | 61 (49.19)                   | 12 (33.33)               | 0.093   |
| Soft                                       | 87 (54.37)      | 63 (50.81)                   | 24 (66.67)               |         |
| Pancreatic diameter (mm), median (rang), n = 160 | 3 (2, 5) | 4 (3, 5)                      | 3 (2, 4)                 | 0.011   |
| Rate of bilirubin decrease, n (%)          |                 |                              |                          |         |
| Adequate rate                              | 39 (23.49)      | 25 (19.23)                   | 14 (38.89)               | 0.014   |
| Inadequate rate                            | 127 (76.51)     | 105 (80.77)                  | 22 (61.11)               |         |

Major morbidity defined as higher than grade II in the Clavien-Dindo classification. SD: standard deviation; BMI: body mass index; DM: diabetes; ASA: American Society of Anesthesiologists; PTBD: percutaneous transhepatic biliary drainage; ERCP: endoscopic retrograde cholangiopancreatography; WBC: white blood cell count; IQR: interquartile range.

PD is very important.21 One of the problems encountered in such patients is obstructive jaundice and malnutrition. Obstructive jaundice alters the function of intestinal microbial flora, Kupffer cell function, and cellular immunity.5 Thus, PBD is indicated for the patient with severe preoperative jaundice and malnutrition.22 However, some studies
reported an increase in infectious complication in patients who received PBD prior to undergoing PD. At Ramathibodi Hospital, the presenting symptom of obstructive jaundice is very prevalent, with most patients having a mean total bilirubin level of 12.5 mg/dL at the time of diagnosis. This value is relatively greater than other previously reported studies. Thus, the PBD rate in our hospital is greater than other reports. The overall rate of bilirubin decrease in our center is 12% within 1 week, which is comparable with other studies. The association between the rate of bilirubin decrease and short-term outcome following PD was rarely reported. An ideal rate of bilirubin decrease after PBD is more than 50% within 1 week. However, most patients did not reach this rate in real clinical practice. Thus, a cutoff point of more

| Data                                      | Univariate | Multivariate |
|-------------------------------------------|------------|--------------|
|                                          | OR (95%CI) | p value      | OR(95%CI)   | p value |
| Waiting time (day) n = 162                |            |              |             |         |
| ⩽30 day                                   |            |              |             |         |
| >30 day                                   | 0.9 (0.4–2.0) | 0.864        |             |         |
| Preoperative cholangitis                   | 1.1 (0.3–3.3) | 0.801        |             |         |
| Age (years)                               | 1.0 (0.9–1.0) | 0.738        |             |         |
| Gender                                    |            |              |             |         |
| Male                                      | 1          |              |             |         |
| Female                                    | 1.3 (0.6–2.7) | 0.460        |             |         |
| BMI (kg/m²)                               | 1.1 (1.0–1.2) | 0.012        | 1.1(1.0–1.2) | 0.040 |
| DM                                        |            |              |             |         |
| No                                        |            |              |             |         |
| Yes                                       | 0.4 (0.1–1.3) | 0.169        |             |         |
| ASA class                                 |            |              |             |         |
| I                                         | 1          |              |             |         |
| II                                        | 0.8 (0.2–3.1) | 0.842        |             |         |
| III                                       | 1.0 (0.3–3.5) | 0.952        |             |         |
| IV                                        | 1.2 (0.1–15.4) | 0.862        |             |         |
| V                                         | -          | -            |             |         |
| Smoking                                   |            |              |             |         |
| No                                        |            |              |             |         |
| Yes                                       | 0.6 (0.2–1.5) | 0.319        |             |         |
| Biliary intervention                      |            |              |             |         |
| PTBD                                      | 1          |              |             |         |
| ERCP                                      | 0.5 (0.0–3.0) | 0.487        |             |         |
| Albumin(g/L)                              | 0.9 (0.8–1.0) | 0.068        |             |         |
| >35                                       | 1          |              |             |         |
| <35                                       | 0.5 (0.2–1.1) | 0.093        |             |         |
| WBC (cells/mm³)                           | 0.9 (0.8–1.1) | 0.647        |             |         |
| Hb (g/dL)                                 | 0.9 (0.9–1.0) | 0.661        |             |         |
| Diagnosis                                 |            |              |             |         |
| Pancreatic cancer                         | 1          |              |             |         |
| Ampullary cancer                          | 2.7 (0.8–8.9) | 0.096        |             |         |
| Duodenal cancer                           | 1.0 (0.1–11.1) | 0.940        |             |         |
| Cholangiocarcinoma                        | 3.9 (0.9–17.4) | 0.067        |             |         |
| Other                                     | 3.4 (0.9–11.9) | 0.052        |             |         |
| Operative time (h)                        | 1.2 (1.0–1.4) | 0.021        | 1.2 (1.0–1.5) | 0.027 |
| Blood loss(ml)                            | 1.0 (0.9–1.0) | 0.060        |             |         |
| Pancreatic texture                        |            |              |             |         |
| Hard/Firm                                 | 1          |              |             |         |
| Soft                                      | 1.9 (0.8–4.2) | 0.096        |             |         |
| Pancreatic duct diameter (mm)             | 0.7 (0.6–0.9) | 0.021        | 0.7 (0.6–0.9) | 0.033 |
| Rate of bilirubin decrease                | 1.1 (0.8–1.5) | 0.342        |             |         |

OR: odds ratio; CI: confidence interval; BMI: body mass index; DM: diabetes; ASA: American Society of Anesthesiologists; PTBD: percutaneous transhepatic biliary drainage; ERCP: endoscopic retrograde cholangiopancreatography; WBC: white blood cell count.
than 20% bilirubin decrease within 7 days suggested by the European Society of Gastrointestinal Endoscopy (ESGE) guideline was adopted in this study as an adequate bilirubin drainage.20 The current study’s result showed that patients who had major morbidity were less likely to have come from the adequate biliary drainage rate group than the inadequate group. However, through logistic regression analysis, the bilirubin decrease rate was not associated with severe short-term outcome following PD. The possible explanation for the contradicting results is that the number of patients who had adequate drainage was not large enough to detect a significant association.

To the best of our knowledge, there is currently no study that explored the relationship between bilirubin decrease rate and postoperative morbidity exclusively in patients who underwent PD. Sano et al. conducted a study in patients who received major hepatobiliary or pancreatic surgery and found that patients with a slower bilirubin decline after PBD had a higher rate of morbidity.19 Moreover, factors associated with a slow rate of bilirubin decrease were age and a prolonged period of undrained jaundice. However, Sano’s study included patients who underwent hepatectomy as well as pancreatic resection, and there is already strong evidence from previously reported studies that performing liver resection in jaundice patients is associated with poor short-term outcomes.27 Thus, the association seen in Sano’s study could have been the effect from the liver resection population.

Based on the study’s results, the factors associated with major morbidity after PD were operative time, pancreatic duct diameter, and BMI. Each factor is discussed in turn. First, with respect to duration of surgery, a prolonged operative time is associated with major morbidity and mortality, as previously reported.28,29 In earlier study, we reported the factors associated with infectious complications in patients who underwent major hepatectomy were reported. It was found that patients who have intraabdominal infection have significantly longer operative time than those in a non-intraabdominal infection group.28 This is consistent with Chacon et al., who studied the effect of operative duration and infectious complications and mortality in a large population of patients who underwent hepatectomy.30 It was found that an operative time greater than 3 h significantly increased mortality, with a considerable peak at 8 h. Furthermore, as the 30-day mortality rate increased in accordance with the operative time, it was concluded that operative time is associated with a linear increase of risk of mortality and infectious complications following hepatectomy. Recently, Coimbra et al. reported the predicting factors for major postoperative morbidity in a large population cohort study.31 They found that the independent factors associated with morbidity consisted of the following: age, chronic obstructive pulmonary disease, coronary heart disease, chronic liver disease, pancreatic resection, and operative time. Usually, PD is a complex operation, with a prolonged operative time. Surgical team communication and proper usage of the surgical safety checklist are effective means of reducing operative time.32

Second, with regard to BMI as a factor, multiple previous studies have proven that BMI is associated with complications following PD.33,34 A possible mechanism is that BMI is a predictor of the percentage of pancreatic fat which, in turn, is a risk factor for POPF.35 Finally, with regard to small pancreatic duct as a factor, such finding was anticipated. A small pancreatic duct diameter is a well-known significant factor for severe complications, including intraabdominal infection and post-pancreatectomy hemorrhage.36,37

This study had a few limitations. First, some selection bias may be present due to the retrospective nature of the study. Second, the study population was relatively small. Third, the waiting time between PBD and PD in the current study is longer than other previous studies.13,38 A prolonged waiting time might be from the congestion of the patient in the high volume center in our country, severe jaundice, and nutritional status of the patient.39 Fourth, there was the variation of the rate of bilirubin decrease in each patient; for example, a patient displayed a good rate of bilirubin decrease in the first week, but a slower rate in the second week. The variation in the drainage rate may or may not affect patients’ outcome and is a potential for further study. Fifth, only two subjects in the study population received metallic stent placement. The population was heavily skewed toward those with plastic stents; thus, the study’s applicability to those with metallic stents would need further investigation in order to be determined. Finally, there is lack of biliary bacteriology data of the study population.

Conclusion

The preoperative optimization of the patient undergoing PD is crucial. PBD is one of the most common interventions for patients with severe jaundice who are scheduled for PD. From our study, only BMI, operative time, and pancreatic duct diameter were the factors associated with major morbidity. Although patients with inadequate bilirubin drainage had higher major morbidity, an association between bilirubin decrease rate and major morbidity could not be established from a multivariate analysis. Thus, a future study with larger population is warranted to confirm or deny this hypothesis.

Acknowledgements

The authors thank Associate Professor Panuwat Lertsithichai and Dr. Napaphat Poprom, PhD, for their data analysis work, and Mr. William Farquharson for his contribution as a language consultant. The authors also express their heartfelt thanks to their data collectors and friends who supported them in this research work.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Narongsak Runsgakulkij https://orcid.org/0000-0003-3522-5800
Watoo Vassanasiri https://orcid.org/0000-0001-5367-9887

References
1. Endo Y, Noda H, Watanabe F, et al. Bridge of preoperative biliary drainage is a useful management for patients undergoing pancreaticoduodenectomy. *Pancretology* 2019; 19(5): 775–780.
2. Ammori JB, Choong K and Hardacre JM. Surgical therapy for pancreatic and periampullary cancer. *Surg Clin North Am* 2016; 96(6): 1271–1286.
3. Sauvanet A, Boher J-M, Paye F, et al. Severe jaundice increases early severe morbidity and decreases long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. *J Am Coll Surg* 2015; 221(2): 380–389.
4. Shen Z, Zhang J, Zhao S, et al. Preoperative biliary drainage of severely obstructive jaundiced patients decreases overall postoperative complications after pancreaticoduodenectomy: a retrospective and propensity score-matched analysis. *Pancretology* 2020; 20(3): 529–536.
5. Pavlidis ET and Pavlidis TE. Pathophysiological consequences of obstructive jaundice and perioperative management. *Hepatobiliary Pancreat Dis Int* 2018; 17(1): 17–21.
6. van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. *N Engl J Med* 2010; 362: 129–137.
7. De Pastena M, Marchegiani G, Paiella S, et al. Impact of preoperative biliary drainage on postoperative outcome after pancreaticoduodenectomy: an analysis of 1500 consecutive cases. *Dig Endosc* 2018; 30(6): 777–784.
8. Roberts KJ, Prasad P, Steele Y, et al. A reduced time to surgery within a “fast track” pathway for periampullary malignancy is associated with an increased rate of pancreaticoduodenectomy. *HPB* 2017; 19(8): 713–720.
9. Dorcaratto D, Hogan NM, MuÅ±oz E, et al. Is percutaneous transhepatic biliary drainage better than endoscopic drainage in the management of jaundiced patients awaiting pancreaticoduodenectomy? A systematic review and meta-analysis. *J Vasc Interv Radiol* 2018; 29(5): 676–687.
10. Wang L, Lin N, Xin F, et al. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. *World J Surg Oncol* 2019; 17: 116.
11. Kagedan DJ, Mosko JD, Dixon ME, et al. Changes in preoperative endoscopic and percutaneous bile drainage in patients with periampullary cancer undergoing pancreaticoduodenectomy in Ontario: effect on clinical practice of a randomized trial. *Curr Oncol* 2018; 25(5): e430–e435.
12. Inamdar S, Slattery E, Bhatta R, et al. Comparison of adverse events for endoscopic vs percutaneous biliary drainage in the treatment of malignant biliary tract obstruction in an inpatient national cohort. *JAMA Oncol* 2016; 2(1): 112–117.
13. Shin SH, Han IW, Ryu Y, et al. Optimal timing of pancreaticoduodenectomy following preoperative biliary drainage considering major morbidity and postoperative survival. *J Hepatobiliary Pancreat Sci* 2019; 26(10): 449–458.
14. Bala L, Tripathi P, Choudhuri G, et al. Restoration of hepatocytes function following decompression therapy in extrahepatic biliary obstructed patients: metabolite profiling of bile by NMR. *J Pharm Biomed Anal* 2011; 56: 54–63.
15. Kato S, Nagano I, Nimura Y, et al. Hepatic recovery after biliary drainage in experimental obstructive jaundice complicated by biliary infection. *Hepatogastroenterology* 1994; 41(3): 217–221.
16. Sano K, Kubota K, Bandai Y, et al. Rate of bilirubin decrease as a risk predictor in hepatobiliary-pancreatic surgery. *Hepatogastroenterology* 1999; 46(28): 2171–2177.
17. Nakayama T, Tamae T, Kinoshita H, et al. Evaluation of surgical risk in preoperative biliary drainage patients by blood chemistry laboratory data—with special reference to rate of reduction of serum bilirubin levels. *Hepatogastroenterology* 1995; 42(4): 338–342.
18. Dindo D, Demartines N and Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; 240(2): 205–213.
19. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. *Surgery* 2017; 161(3): 584–591.
20. Dumonceau JM, Tringali A, Blero D, et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. *Endoscopy* 2012; 44: 277–298.
21. Wang XY, Cui JP, Huang CS, et al. Impact of enhanced recovery after surgery protocol on pancreaticoduodenectomy: a meta-analysis of non-randomized and randomized controlled trials. *HPB (Oxford)* 2020; 22(10): 1373–1383.
22. Lin S-C, Shan Y-S and Lin PW. Adequate preoperative biliary drainage and major morbidity after pancreatoduodenectomy: a retrospective and propensity score-matched analysis. *Hepatobiliary Pancreat Sci* 2019; 26(10): 449–458.
23. Lee H, Han Y, Kim JR, et al. Preoperative biliary drainage adversely affects surgical outcomes in periampullary cancer: a retrospective and propensity score-matched analysis. *J Hepatobiliary Pancreat Sci* 2018; 25(3): 206–213.
24. Sandini M, Honselmann KC, Birnbaum DJ, et al. Preoperative biliary stenting and major morbidity after pancreaticoduodenectomy: does elapsed time matter? The FRAGERITA Study Group. *Ann Surg* 2018; 268(5): 808–814.
25. Shimizu T, Sato O and Tsukada K. Reestimation of the bilirubin decrease rate “b” (b value) in patients with obstructive jaundice. *Journal of Hepato-biliary-pancreatic Surgery* 1996; 3: 12–16.
26. Watanapa P. Recovery patterns of liver function after complete and partial surgical biliary decompression. *Am J Surg* 1996; 171(2): 230–234. doi:
27. Sahara K, Merath K, Hyer JM, et al. Impact of Preoperative Cholangitis on Short-term Outcomes Among Patients Undergoing Liver Resection. *J Gastrointest Surg* 2020; 24: 2508–2516.
28. Rungsakulkij N, Vassanasiri W, Tangtawee P, et al. Preoperative serum albumin is associated with intra-abdominal infection following major hepatectomy. *J Hepatobiliary Pancreat Sci* 2019; 26(11): 479–489.

29. Tracy BM, Paterson CW, Torres DM, et al. Risk factors for complications after cholecystectomy for common bile duct stones: an EAST multicenter study. *Surgery* 2020; 168(1): 62–66.

30. Chacon E, Eman P, Dugan A, et al. Effect of operative duration on infectious complications and mortality following hepatectomy. *HPB* 2019; 21(12): 1727–1733.

31. Coimbra FJF, de Jesus VHF, Franco CP, et al. Predicting overall and major postoperative morbidity in gastric cancer patients. *J Surg Oncol* 2019; 120(8): 1371–1378.

32. Haynes AB, Weiser TG, Berry WR, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. *N Engl J Med* 2009; 360: 491–499.

33. Chang EH, Sugiyama G, Smith MC, et al. Obesity and surgical complications of pancreaticoduodenectomy: an observation study utilizing ACS NSQIP. *Am J Surg* 2020; 220(1): 135–139.

34. Williams TK, Rosato EL, Kennedy EP, et al. Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. *J Am Coll Surg* 2009; 208(2): 210–217.

35. Rosso E, Casneci S, Pessaux P, et al. The role of “fatty pancreas” and of BMI in the occurrence of pancreatic fistula after pancreaticoduodenectomy. *J Gastrointest Surg* 2009; 13(10): 1845–1851.

36. Ryu Y, Shin SH, Park DJ, et al. Validation of original and alternative fistula risk scores in postoperative pancreatic fistula. *J Hepatobiliary Pancreat Sci* 2019; 26: 354–359.

37. Mungroop TH, van Rijssen LB, van Klaveren D, et al. Alternative fistula risk score for pancreaticoduodenectomy (a-FRS): design and international external validation. *Ann Surg* 2019; 269: 937–943.

38. Yang F, Jin C, Zou C, et al. Delaying surgery after preoperative biliary drainage does not increase surgical morbidity after pancreaticoduodenectomy. *Surgery* 2019; 166: 1004–1010.

39. Rungsakulkij N, Tangtawee P, Suragul W, et al. Correlation of serum albumin and prognostic nutritional index with outcomes following pancreaticoduodenectomy. *World J Clin Cases* 2019; 7: 28–38.